Ketorolac trometamol topical formulations: Release behaviour, physical characterization, skin permeation, efficacy and gastric safety

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 1, 2010, Pages 25-34

  El Setouhya, Doaa Ahmed ^a   El Ashmony, Sahar Mohy Ahmed ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Analgesic; Anti inflammatory activity; Ketorolac trometamol; Transdermal delivery

Indexed keywords

KETOROLAC TROMETAMOL;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; GEL; HOT PLATE TEST; IN VITRO STUDY; INFLAMMATION; MALE; MICROEMULSION; NEWBORN; NONHUMAN; PAIN; PAW EDEMA; RAT; SKIN PENETRATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MODELS, ANIMAL; EMULSIONS; EXCIPIENTS; GELS; INFLAMMATION; KETOROLAC TROMETHAMINE; MALE; MYRISTATES; PLANT OILS; POLYETHYLENE GLYCOLS; PROPYLENE GLYCOL; RATS; SKIN ABSORPTION; STOMACH ULCER;

EID: 77949494608     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/62.01.0002     Document Type: Article

References (40)

1. Buckley MM, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1990; 39: 86-109.
2. Angeles González-Fernández M. Appropriateness of ketorolac use in a trauma hospital. Rev Calid Asist 2009; 24: 115-123.
3. Mercadante S et al. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer 2002; 38: 1358-1363.
4. Joishy SK, Walsh D. The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome. J Pain Symptom Manage 1998; 16: 334-339.
5. Gillis JC, Brogden RN. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53: 139-188.
6. Kearns GL et al. Percutaneous lidocaine administration via a new iontophoresis system in children: tolerability and absence of systemic bioavailability. Pediatrics 2003; 112: 578-582.
7. Cho YA, Gwak HS. Transdermal delivery of ketorolac tromethamine: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm 2004; 30: 557-564.
8. Alsarra IA et al. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm 2005; 59: 485-490.
9. Nagarsenker MS et al. Potential of cyclodextrin complexation and liposomes in topical delivery of ketorolac: in vitro and in vivo evaluation. AAPS PharmSciTech 2008; 9: 1165-1170.
10. Kim BY et al. Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies. Int J Pharm 2005; 293: 193-202.
11. Tiwari SB, Udupa N. Investigation into the potential of iontophoresis facilitated delivery of ketorolac. Int J Pharm 2003; 260: 93-103.
12. Yang J et al. Anti-hyperalgesic and anti-inflammatory effects of ketorolac tromethamine gel using pulsed ultrasound in inflamed rats. Arch Pharm Res 2008; 31: 511-517.
13. Kale NJ, Allen LV. Studies on microemulsions using brij as surfactant and glycerin, ethylene glycol and propylene glycol as cosurfactants. Int J Pharm 1989; 57: 87-93.
14. Wu H et al. Topical transport of hydrophilic compounds using water in oil nanoemulsions. Int J Pharm 2001; 220: 63-75.
15. Devi K, Paranjothy KL. Pharmacokinetic profile of a new matrix-type transdermal delivery system: diclofenac diethyl ammonium patch. Drug Dev Ind Pharm 1999; 25: 695-700.
16. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961; 50: 874-875.
17. Sung KC. Delivery of nalbuphine and its prodrugs across skin by passive diffusion and iontophoresis. J Control Release 2000; 67: 1-8.
18. Habib BA et al. Factorial design approach for optimization of a gel formulation for in-vitro iontophoretic transdermal delivery of granisetron. Bull Fac Pharm 2008; 46: 305-313.
19. Roy SD, Manoukian E. Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. J Pharm Sci 1995; 84: 1190-1196.
20. Meidan VM et al. Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers. Int J Pharm 2003; 264: 73-83.
21. Patel SR et al. In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. Eur J Pharm Biopharm 2007; 66: 296-301.
22. Granados-Soto V, Flores-Murrieta FJ. Pharmacokinetics of oral ketorolac in the rat. Methods Find Exp Clin Pharmacol 1995; 17: 535-538.
23. Wiesenfeld-Hallin Z et al. Studies of hyperalgesia induced by Trypanosoma brucei brucei infection in rats. Acta Trop 1991; 48: 215-222.
24. Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957; 111: 409-419.
25. Winter CA, Porter CC. Effect of alteration in side chain upon anti-inflammatory and liver glycogen activities in hydrocortisone ester. J Am Pharmacol Soc 1957; 46: 515-519.
26. Seyle H. Further studies concerning the participation of adrenal cortex in the pathogenesis of arthritis. Br Med J 1949; 2: 1129-1135.
27. Santucci L et al. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. Gut 1994; 35: 909-915.
28. Perretti et al. Reduction of aspirin induced gastric damage in rats by interleukin-1B; possible involvement of endogenous corticosteroids. J Pharmacol Exp Ther 1992; 261: 1238-1247.
29. Ruiz Martinez MA et al. Rheological behavior of gels and meloxicam release. Int J Pharm 2007; 333: 17-23.
30. Higuchi WI. Analysis of data on the medicament release from ointments. J Pharm Sci 1962; 51: 802-804.
31. Perioli L. Rheological and functional characterization of new anti-inflammatory delivery system designed for buccal administration. Int J Pharm 2008; 356: 19-28.
32. Sood A, Panchagnula R. Role of dissolution studies in controlled release drug delivery system. STP Pharmaceutical Science 1999; 9: 157-168.
33. Ho HO et al. The influence of co solvents on the in-vitro percutaneous penetration of diclofenac sodium from a gel system. J Pharm Pharmacol 1994; 46: 636-642.
34. Harrison JE et al. The relative effect of azone and transcutol on permeant diffusivity and solubility in human stratum corneum. Pharm Res 1996; 13: 542-546.
35. Rhee YS et al. Transdermal delivery of ketoprofen using microemulsions. Int J Pharm 2001; 228: 161-170.
36. Abd El-Bary A et al. Bioavailability of sulbutamol from different suppository formulations. Egypt Journal of Pharmaceutical Science 1992; 33: 1031-1043.
37. Friedman DI et al. Submicron emulsion vehicle for enhanced transdermal delivery of steroidal and nonsteroidal anti-inflammatory drugs. J Pharm Sci 1995; 84: 324-329.
38. Gao S, Singh J. Effect of oleic acid/ethanol and oleic acid/propylene glycol on the percutaneous absorption of 5-fluorouracil and tamoxifen and the macroscopic barrier property of porcine epidermis. Int J Pharm 1998; 165: 45-55.
39. Bosek V, Cox CE. Comparison of analgesic effect of locally and systemically administered ketorolac in mastectomy patients. Ann Surg Oncol 1996; 3: 62-66.
40. Cordero JA. In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs. Eur J Pharm Biopharm 2001; 51: 135-142.